WNK2 and Parkinson disease: Mitogen-activated protein kinase (MAPK) pathway and phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway are two other important signals indicating the intervention of HSYA in the treatment of Parkinson's disease (PD) [40], asthma [41], non-small-cell lung cancer [42], and brain microvascular endothelial injury [43].